97114 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus Retroviridae, e.g. leukemia viruses
Sub-classes:RECOMBINANT POLYPEPTIDES COMPRISING SINGLE-DOMAIN ANTIBODIES TARGETING HERV-K SUBTYPE HML-2
#2HERV-K ANTIBODY, CELL, VACCINE, AND DRUG THERAPEUTICS
#3ANTIBODIES HAVING PAN-ANTIVIRAL ACTIVITY AND METHODS THEREOF
#4VIRAL CLEARANCE BY LOW PH HOLD
#5HERV-K ANTIBODY THERAPEUTICS
#6ANTI-HERV-W ENVELOPE PROTEIN ANTIBODY FOR USE IN THE TREATMENT OF PSYCHOTIC DISEASES
#7ANTIGEN-BINDING AND ANTIGEN DEGRADATION CONSTRUCTS
#8HERV INHIBITORS FOR USE IN TREATING TAUOPATHIES
#9VECTORIZED ANTIBODIES AND USES THEREOF
#10Viral clearance by low pH hold
#11Antibodies that bind interleukin-10 receptor-2 peptides, compositions, and methods of use thereof
#12Anti-HERV-K envelope protein antibodies and methods for detecting HERV-K envelope protein in patients with sporadic amyotrophic lateral sclerosis
#13Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
#14HUMAN ENDOGENOUS RETROVIRAL PROTEIN
#15Methods for alleviating symptoms of sporadic amyotrophic lateral sclerosis by neutralizing a HERV-K envelope protein using an anti-HERV-K envelope protein antibody
#16Growth differentiation factor 15 agonist compounds and methods of using the same
#17Antiretroviral drug targeting human endogenous retrovirus
#18Methods for determining spatial and temporal gene expression dynamics in single cells
#19Interleukin-10 receptor-2 peptides, antibodies, compositions, and methods of use thereof
#20Monoclonal antibody to treat alzheimer's disease, prion disease, frontotemporal dementias and traumatic brain injury/chronic traumatic encephalopathy
#21IL2R common gamma chain antibodies
#22Method for expansion of a population of cells with IL2R beta/common gamma chain antibodies
#23IL-2R beta/common gamma chain antibodies
#24PEST CONTROL SYSTEM
#25Compounds for treating the remyelination blockade in diseases associated with the expression of HERV-W envelope protein
#26Therapeutic use of specific ligand in MSRV associated diseases
#27Methods for the diagnosis of cancer through detection of human endogenous retrovirus WL (HERV-WL) envelope expression
#28Therapeutic use of specific ligand in MSRV associated diseases
#29Method of treating cancer using IL2R beta/common gamma chain antibodies
#30Methods for producing peptides including HERV-W envelope motifs and for producing antibodies specific for the peptides
#31METHODS AND KITS FOR THE DETECTION OF VIRAL INFECTIONS
#32Compounds for treating the remyelination blockade in diseases associated with the expression of HERV-W envelope protein
#33Novel Antibodies and Uses Thereof
#34Therapeutic use of specific ligand in MSRV associated diseases
#35NOVEL SIMIAN T-CELL LYMPHOTROPIC VIRUS
#36HERV-K antigens, antibodies, and methods
#37Novel Antibodies and Uses Thereof
#38Gammaretrovirus Associated With Cancer
#39Markers of XMRV Infection And Uses Thereof
#40MARKERS OF XMRV INFECTION AND USES THEREOF
#41Therapeutic use of specific ligand in MSRV associated diseases
#42Markers of XMRV infection and uses thereof
#43Markers of XMRV Infection and Uses Thereof
#44Melanoma-Associated Endogenous Retrovirus (MERV) Derived Peptide Sequences And Their Therapeutic/Diagnostic Use
#45In vitro human B lymphopoiesis culture system
#46Gammaretrovirus associated with cancer
#47Simian T-cell lymphotropic virus
#48Antibodies specific for the melanoma-associated endogenous retrovirus (MERV) envelope glycoprotein
#49PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES DIRECTED AGAINST THE HERV-W ENVELOPE
#50HERV-K ANTIGENS, ANTIBODIES, AND METHODS
#51Peptide Domain Required For Interaction Between The Envelope of a Virus Pertaining to The Herv-W Interference Group and an Hasct Receptor
#52Melanoma-associated endogenous retrovirus (MERV) derived peptide sequences and their therapeutic/diagnostic use
#53Composition for treating pathology associated with MSRV/HERV-W
#54HERV-K Antigens, Antibodies, and Methods
#55Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA's
#56Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses
#57Intracellular antibodies for a retrovirus protein
#58Intracellular antibodies for a retrovirus protein